All Paxlovid articles
-
NewsOld molecules show promise for fighting resistant strains of COVID-19 virus
SARS‑CoV‑2 continues to mutate, with some newer strains becoming less responsive to current antiviral treatments like Paxlovid. Now, researchers have identified several promising molecules that could lead to new medications capable of combating these resistant variants.
-
NewsStudy of oral azvudine versus nirmatrelvir/ritonavir in elderly hospitalized COVID-19 patients
A study used five analytical methods to show that oral azvudine has a therapeutic effect in elderly COVID-19 patients aged over 60 years.
-
NewsNew COVID-19 drug shows greater promise against resistant viral strains
A new standalone oral drug candidate has proven to be effective against Paxlovid-resistant COVID-19 strain in animal models. It works with low doses and cause no drug interaction-induced side effects.
-
NewsPaxlovid’s impact on hospitalization and death in COVID-vaccinated older adults far weaker than previously thought
A new study overturns the assumption that Paxlovid’s effectiveness in reducing COVID-19 hospitalizations and deaths in unvaccinated adults also applies to vaccinated adults.
-
NewsA new class of antivirals could help prevent future pandemics
A new study introduces a proof-of-concept for a novel class of antivirals that would target a type of enzyme essential not just to SARS, but also many RNA viruses, including Ebola and dengue, as well as cytosolic-replicating DNA viruses, including Pox viruses.
-
NewsScientists assess efficacy of clinical drugs targeting SARS-CoV-2 main protease
A critical player in the virus’s life cycle is the main protease (Mpro), also known as NSP5 or 3CL protease, which plays a crucial role in the cleavage and maturation of SARS-CoV-2 proteins within the host cells.
-
NewsAntiviral-resistant variants of SARS-CoV-2 can emerge in immunocompromised people
Individuals with compromised immunity and persistent COVID-19 infections can harbor drug-resistant variants of the SARS-CoV-2 virus, which have the potential to spread to the general population.
-
NewsOptimal timing maximises Paxlovid benefits for treating COVID-19
Study suggests using the anti-COVID-19 treatment Paxlovid three to five days after symptoms emerge in patients and expanding global access to the drug may help reduce the severity and transmission of the SARS-CoV-2 virus.
-
NewsScientists uncover how coronavirus defends itself against our immune system
A research team identifies “protective switches” in the protein of the SARS-CoV-2 virus.
-
NewsOne in five patients experience rebound COVID after taking Paxlovid, new study finds
While Paxlovid remains a ‘life-saving drug,’ researchers found that patients experiencing virologic rebound after treatment may remain contagious.
-
NewsMolnupiravir dose of human effect size-equivalent blocks Covid transmission in ferrets
Two oral drugs provide equivalent therapeutic benefit in preventing severe COVID-19 in animal models, but only molnupiravir efficiently blocked SARS-CoV-2 transmission when administered at a human effect size-equivalent dose.
-
NewsResearchers use mass spectrometry to explore antimicrobial resistance
Researchers are using single-cell mass spectrometry to determine whether cells with persistent pathogens will also have less intracellular drug levels to potentially explain antimicrobial treatment failure.
-
NewsStudy finds evidence of resistance to COVID-19 drugs
Resistance to Paxlovid is already evident among viral SARS-CoV-2 variants currently circulating globally, indicating that this stand-alone drug known as a protease inhibitor could soon become less effective in treating COVID-19 infections, a new study suggests.